GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute

GSK's subsidiary TESARO has filed suit against AnaptysBio in Delaware Chancery Court alleging material breach of their March 2014 license for Jemperli (dostarlimab), seeking to terminate the agreement, secure a perpetual license and cut royalties and milestone payments by 50%. The move follows AnaptysBio's attempt to revoke the license—characterized by GSK/TESARO as "entirely without merit"—and arrives as Jemperli, approved in more than 35 countries for certain endometrial cancers, is seeing significant growth from label expansions and is being studied in additional indications. GSK did not disclose specifics of the alleged breaches or a timetable for the litigation, leaving near-term commercial and revenue implications for both parties uncertain.

Analysis

GSK's subsidiary TESARO has filed suit against AnaptysBio in the Delaware Chancery Court alleging a material breach of the parties' March 2014 license for Jemperli (dostarlimab); TESARO seeks termination of the agreement, a perpetual license for the asset and a 50% reduction in royalties and milestone payments. AnaptysBio reportedly intends to revoke TESARO’s license and characterizes TESARO/GSK's claims as "entirely without merit," while neither side disclosed specifics of the alleged breaches or a timetable for litigation. Jemperli is approved in more than 35 countries for certain endometrial cancers and GSK reports significant growth driven by label expansions in the U.S. and EU; GSK is also running trials in rectal, colon and head and neck cancers, which supports upside to future indications. Market signals flag a mildly negative sentiment overall (score -0.3) with per-ticker sentiment positive for GSK (0.3) and materially negative for AnaptysBio (-0.6), and a modest market impact score (0.35), implying the dispute is potentially disruptive to AnaptysBio equity and presents a binary legal-commercial risk for future royalty flows to AnaptysBio and operating leverage for GSK depending on outcome.

Key Decisions for Investors

• Monitor Delaware Chancery filings and any scheduled hearing dates for concrete disclosure of alleged breaches and remedies as these will re‑price binary legal risk quickly
• Consider underweighting or hedging AnaptysBio equity exposure until the court clarifies license status or a settlement appears likely given the strongly negative per‑ticker sentiment and lack of disclosed timeline